Granted Patent
B2
US 12,324,810 · App. 18/595,985 · Granted Jun 10, 2025
3, 7-diamino-10H-phenothiazine salts and their use
Inventors:
Claude Michel Wischik (Aberdeen, GB); Janet Elizabeth Rickard (Aberdeen, GB); Charles Robert Harrington (Aberdeen, GB); David Horsley (Aberdeen, GB); John Mervyn David Storey (Aberdeen, GB); Colin Marshall (Aberdeen, GB); James Peter Sinclair (Aberdeen, GB); Thomas Craven Baddeley (Aberdeen, GB)
Assignee:
WisTa Laboratories Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R 1 and R 9 are independently selected from: —H; C 1-4 alkyl; C 2-4 alkenyl; and halogenated C 1-4 alkyl; each of R 3NA and R 3NB is independently selected from: —H; C 1-4 alkyl; C 2-4 alkenyl; and halogenated C 1-4 alkyl; each of R 7NA and R 7NB is independently selected from: —H; C 1-4 alkyl; C 2-4 alkenyl; and halogenated C 1-4 alkyl; each of HX 1 and HX 2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.
Claims (34)
1. A method of treatment of fronto-temporal dementia in a subject in need thereof,
the method comprising administering to the subject a therapeutically effective amount of a bis protic acid salt compound of the following formula:
wherein:
each of R 1 and R 9 is independently selected from the group consisting of: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl;
each of R 3NA and R 3NB is independently selected from the group consisting of: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl;
each of R 7NA and R 7NB is independently selected from the group consisting of: —H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; and
each of HX 1 and HX 2 is independently a protic acid, wherein if any of HX 1 or HX 2 is a hydrohalic acid, then each is independently selected from the group consisting of HCl and HBr.
2. The method according to claim 1 , wherein each of R 1 and R 9 is independently —H, -Me, -Et, or —CF 3 .
3. The method according to claim 1 , wherein each of R 1 and R 9 is independently —H, -Me, or -Et.
4. The method according to claim 1 , wherein R 1 and R 9 are the same.
5. The method according to claim 1 , wherein each of R 1 and R 9 is independently —H.
6. The method according to claim 1 , wherein each of R 3NA and R 3NB is independently -Me, -Et, -nPr, -nBu, —CH 2 —CH═CH 2 , or —CF 3 .
7. The method according to claim 1 , wherein R 3NA and R 3NB are the same.
8. The method according to claim 1 , wherein each of R 7NA and R 7NB is independently -Me, -Et, -nPr, -nBu, —CH 2 —CH═CH 2 , or —CF 3 .
9. The method according to claim 1 , wherein R 7NA and R 7NB are the same.
10. The method according to claim 1 , with the proviso that:
at least one of R 3NA and R 3NB and R 7NA and R 7NB is other than-Et.
11. The method according to claim 1 , with the proviso that:
if: each of R 1 and R 9 is —H;
then: R 3NA and R 3NB and R 7NA and R 7NB are not each -Et.
12. The method according to claim 1 , wherein each of the groups —N(R 3NA )(R 3NB ) and —N(R 7NA )(R 7NB ) is independently selected from the group consisting of: -NMe 2 , -NEt 2 , —N(nPr) 2 , —N(Bu) 2 , —NMeEt, —NMe(nPr), and —N(CH 2 CH═CH 2 ) 2 .
13. The method according to claim 1 , wherein the groups —N(R 3NA )(R 3NB ) and —N(R 7NA )(R 7NB ) are the same, and are selected from the group consisting of: —NMe 2 and —NEt 2 .
14. The method according to claim 1 , wherein the groups —N(R 3NA )(R 3NB ) and —N(R 7NA )(R 7NB ) are the same.
15. The method according to claim 1 , with the proviso that: each of the groups —N(R 3NA )(R 3NB ) and —N(R 7NA )(R 7NB ) is other than —NEt 2 .
16. The method according to claim 1 , wherein the groups —N(R 3NA )(R 3NB ) and —N(R 7NA )(R 7NB ) are the same, and are selected from the group consisting of: —NMe 2 , —N(nPr) 2 , —N(Bu) 2 , —NMeEt, —NMe(nPr), and —N(CH 2 CH═CH 2 ) 2 .
17. The method according to claim 1 , wherein each of the groups —N(R 3NA )(R 3NB ) and —N(R 7NA )(R 7NB ) is: —NMe 2 .
18. The method according to claim 1 , wherein each of HX 1 and HX 2 is independently a monoprotic acid.
19. The method according to claim 1 , wherein each of HX 1 and HX 2 is independently a hydrohalide acid.
20. The method according to claim 1 , wherein each of HX 1 and HX 2 is independently an organic acid.
21. The method according to claim 1 , wherein the compound is administered as a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent.
22. The method according to claim 21 , wherein the pharmaceutical composition is a dosage unit which comprises 20 to 300 mg of the compound.
23. The method according to claim 22 , wherein the pharmaceutical composition is a dosage unit which comprises about 30 mg of the compound.
24. The method according to claim 22 , wherein the dosage unit is a tablet or capsule.
25. The method according to claim 1 , wherein the administering is oral.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 9, 2024
From: WISCHIK, CLAUDE MICHEL; STOREY, JOHN MERVYN DAVID; MARSHALL, COLIN; SINCLAIR, JAMES PETER; BADDELEY, THOMAS CRAVEN; RICKARD, JANET ELIZABETH; HARRINGTON, CHARLES ROBERT; HORSLEY, DAVID
To: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
Reel/Frame 068235/0343 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 9, 2024
From: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
To: TAURX THERAPEUTICS LTD
Reel/Frame 068235/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 9, 2024
From: TAURX THERAPEUTICS LTD
To: WISTA LABORATORIES LTD.
Reel/Frame 068236/0274 →
Continuity (7)
References Cited (316)
US 2928767A
· Gulesich et al.
· 1960
[cited by applicant]
US 4309255A
· Gendler et al.
· 1982
[cited by applicant]
US 4622395A
· Bellus et al.
· 1986
[cited by applicant]
US 4647525A
· Miller
· 1987
[cited by applicant]
US 5095011A
· Kaplan et al.
· 1992
[cited by applicant]
US 5220009A
· Mazur et al.
· 1993
[cited by applicant]
US 5693638A
· Myers
· 1997
[cited by applicant]
US 5827644A
· Floyd et al.
· 1998
[cited by applicant]
US 6068854A
· Wunderlich et al.
· 2000
[cited by applicant]
US 6376205B1
· Wischik et al.
· 2002
[cited by applicant]
US 6953794B2
· Wischik et al.
· 2005
[cited by applicant]
US 7737138B2
· Wischik et al.
· 2010
[cited by applicant]
US 7888350B2
· Wischik et al.
· 2011
[cited by applicant]
US 8263589B2
· Wischik et al.
· 2012
[cited by applicant]
US 8278298B2
· Wischik et al.
· 2012
[cited by applicant]
US 8710051B2
· Wischik et al.
· 2014
[cited by applicant]
US 9149481B2
· Wischik et al.
· 2015
[cited by applicant]
US 9174954B2
· Wischik et al.
· 2015
[cited by applicant]
US 9211294B2
· Wischik et al.
· 2015
[cited by applicant]
US 9283230B2
· Clunas et al.
· 2016
[cited by applicant]
US 9907804B2
· Marshall et al.
· 2018
[cited by applicant]
US 20020103189A1
· Miyamoto et al.
· 2002
[cited by applicant]
US 20020197258A1
· Ghanbari et al.
· 2002
[cited by applicant]
US 20030181389A1
· Wtilfert et al.
· 2003
[cited by applicant]
US 20060014216A1
· Wischik et al.
· 2006
[cited by applicant]
US 20070116757A1
· Rariy et al.
· 2007
[cited by applicant]
DE 4430091A1
· 1996
[cited by applicant]
EP 0457295A2
· 1991
[cited by applicant]
EP 0618968B1
· 1994
[cited by applicant]
EP 0737671A2
· 1996
[cited by applicant]
EP 0909814A2
· 1999
[cited by applicant]
EP 0911390A2
· 1999
[cited by applicant]
EP 0911398A2
· 1999
[cited by applicant]
EP 1067386B1
· 2001
[cited by applicant]
FR 2788436A1
· 2000
[cited by applicant]
JP H06289015A
· 1994
[cited by applicant]
WO WO8903993A1
· 1989
[cited by applicant]
WO WO9303177A1
· 1993
[cited by applicant]
WO WO9303369A1
· 1993
[cited by applicant]
WO WO9311231A1
· 1993
[cited by applicant]
WO WO9505466A1
· 1995
[cited by applicant]
WO WO9505601A1
· 1995
[cited by applicant]
WO WO9604915A1
· 1996
[cited by applicant]
WO WO9605837A1
· 1996
[cited by applicant]
WO WO9630766A1
· 1996
[cited by applicant]
WO WO9831219A1
· 1998
[cited by applicant]
WO WO9962548A1
· 1999
[cited by applicant]
WO WO0153340A2
· 2001
[cited by applicant]
WO WO0203972A2
· 2002
[cited by applicant]
WO WO0204025A1
· 2002
[cited by applicant]
WO WO02055720A2
· 2002
[cited by applicant]
WO WO02059150A2
· 2002
[cited by applicant]
WO WO02075318A2
· 2002
[cited by applicant]
WO WO03007933A1
· 2003
[cited by applicant]
WO WO2005030676A1
· 2005
[cited by applicant]
WO WO2005054217A1
· 2005
[cited by applicant]
WO WO2006032879A2
· 2006
[cited by applicant]
WO WO2007110627A2
· 2007
[cited by applicant]
WO WO2007110629A1
· 2007
[cited by applicant]
WO WO2007110630A1
· 2007
[cited by applicant]
WO WO2008007074A2
· 2008
[cited by applicant]
WO WO2008155533A2
· 2008
[cited by applicant]
WO WO2009044127A1
· 2009
[cited by applicant]
Young et al. Ther. Adv. Psychopharmacol 8(1) 2018.
[cited by examiner]
Boeve et al. Lancet Neurol. 21:258-272 (2022).
[cited by examiner]
International Search Report and Written Opinion for Application No. PCT/GB2007/001103, mailed Sep. 7, 2007.
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/GB2007/001103, mailed Jul. 31, 2008.
[cited by applicant]
International Search Report and Written Opinion issue in related International patent Application No. PCT/GB2011/001221, mailed Nov. 3, 2011.
[cited by applicant]
International Preliminary Report on Patentability for PCT/GB2011/001221 dated Aug. 22, 2013 (6 pages).
[cited by applicant]
International Search Report of the corresponding application PCT/GB2008/003315, dated Jan. 22, 2009.
[cited by applicant]
International Preliminary Report on Patentability for PCT/GB2008/003315 dated Apr. 7, 2010.
[cited by applicant]
Examination Report for Application No. BR112013020539-3, mailed Jul. 12, 2021.
[cited by applicant]
Non-Final Office Action mailed May 27, 2010 in U.S. Appl. No. 12/294,599, 14 pages.
[cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 16/248,746 dated Mar. 20, 2019.
[cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 15/056,610 dated Feb. 2, 2017 (14 pages).
[cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 13/011,797 dated Sep. 27, 2012.
[cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 14/248,730 dated Sep. 18, 2014.
[cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 14/929,111 dated May 16, 2016.
[cited by applicant]
United States Office Action for U.S. Appl. No. 96/000,137, mailed Mar. 1, 2016.
[cited by applicant]
Final Office Action issued in U.S. Appl. No. 13/011,797 dated May 21, 2013.
[cited by applicant]
Final Office Action issued in U.S. Appl. No. 14/866,035 dated Dec. 13, 2016 (12 pages).
[cited by applicant]
Final Office Action issued in U.S. Appl. No. 16/248,746 dated Sep. 19, 2019.
[cited by applicant]
Notice of Allowance issued in U.S. Appl. No. 13/011,797 dated Dec. 12, 2013.
[cited by applicant]
Notice of Allowance issued in U.S. Appl. No. 14/248,730 dated Mar. 25, 2015.
[cited by applicant]
Notice of Allowance mailed Oct. 19, 2010 in U.S. Appl. No. 12/294,599, 4 pages.
[cited by applicant]
Indian Hearing Notice for Application No. 7375/DELNP/2013, issued Feb. 9, 2021.
[cited by applicant]
Argentinian Office Action for Application No. 20110102969, dated Sep. 16, 2019.
[cited by applicant]
Argentinian Office Action for Application No. 20110102969, dated Aug. 5, 2020.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/056,610 dated Feb. 2, 2017.
[cited by applicant]
Notification of Reexamination for CN Application No. 201510002365.2, mailed Dec. 19, 2019.
[cited by applicant]
US Final Office Action issued in U.S. Appl. No. 14/866,035 dated Dec. 13, 2016.
[cited by applicant]
US Final Office Action issued in U.S. Appl. No. 14/929,111 dated Mar. 16, 2021.
[cited by applicant]
US Non-Final Office Action issued in U.S. Appl. No. 14/929,111 dated Sep. 14, 2020.
[cited by applicant]
Decision of Final Rejection for CN Application No. 201510002365.2, mailed Dec. 18, 2018.
[cited by applicant]
[No Author Listed] Cecil Textbook of Medicine. 20th Edition. Vol. 2. 1996. Bennett et al., Eds.1739-47.
[cited by applicant]
[No Author Listed] FDA Orange Book, available at https://www.fda.gov/drugs/development-approval-process-drugs/orange-book-preface. Last accessed May 13, 2020. 27 pages.
[cited by applicant]
Aizawa et al., “Microtubule-binding domain of tau proteins,” Journal of Biological Chemistry, 1988, vol. 263, pp. 7703-7707.
[cited by applicant]
Allen et al., “Further clinical experience with toluidine blue and protamine sulfate”, Abnormal Bleeding II, 1949, vol. 89, No. 6, pp. 692-703.
[cited by applicant]
Andersen, “Amyotrophic Lateral Sclerosis Associated with Mutations in the CuZn Superoxide Dismutase Gene”, Current Neurology and Neuroscience Reports, 2006, vol. 6, pp. 37-46.
[cited by applicant]
Anderton et al., “Dendritic Changes in Alzheimer's Disease and Factors That May Underlie these Changes,” Prog. Neurobiol., Aug. 1998., pp. 595-609, vol. 55, No. 6.
[cited by applicant]
Arai et al., “Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy”, Neuropathology, 2010, vol. 30, pp. 170-181, doi:10.1111/j.1440-1789.200…
[cited by applicant]
Askanas et al., “Inclusion Body Myositis: A Degenerative Muscle Disease Associated with Intra-Muscle Fiber Multi-Protein Aggregates, Proteasome Inhibition, Endoplasmic Reticulum Stress and Decreased Lysosomal Degradatio…
[cited by applicant]
Avila et al., Assorted Proteins, Harwood Aend Publishers, Amsterdam, 1997.
[cited by applicant]
Bancher et al., “Accumulation of abnormally phosphorylated T precedes the formation of neurofibrillary tangles in Alzheimer's disease,” Brain Research, 1989, vol. 477, pp. 90-99.
[cited by applicant]
Barmada et al., “Cytoplasmic Mislocalization of TDP-43 is Toxic to Neurons and Enhanced by a Mutation Associated with Familial Amyotrophic Lateral Sclerosis”, J. Neurosci., Jan. 13, 2010, vol. 30, No. 2, pp. 639-649.
[cited by applicant]
Baxman et al., Effect of Vitamin C Supplements on Urinary Oxalate and pH in Calcium Stone-forming Patients. Kidney International. 2003; 63(3):1066-1071.
[cited by applicant]
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 66(1):1-19 (Jan. 1977).
[cited by applicant]
Bernthsen, Studies in the methylene blue group. In: Justus Liebig's Annalen der Chemie. Band 230. Apr. 16, 1885. Kopp et al., Eds.:137-211. German.
[cited by applicant]
Bernthsen, Studies in the methylene blue group. In: Justus Liebig's Annalen der Chemie. Band 230. Jul. 7, 1885. Kopp et al., Eds.:73-136. German.
[cited by applicant]
Bernthsen, Studies in the methylene blue group. In: Justus Liebig's Annalen der Chemie. Band 251. Nov. 1, 1889. Kopp et al., Eds.:1-97. German.
[cited by applicant]
Biernat et al., “The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region,” EMBO Journal 11, 1992, pp. 1593-1597.
[cited by applicant]
Black et al., Structure, Solubility, Screening, and Synthesis of Molecular Salts. J Pharm Sci. May 2007;96(5):1053-68. doi: 10.1002/jps.20927.
[cited by applicant]
Blair et al., “FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis”, J Neurol Neurosurg Psychiatry, doi:10.1136/jnnp.2009.194399, 2010, vol. 81, pp. 639-645.
[cited by applicant]
Bondareff et al., “Immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease”, Journal of Neuropathology and Experimental Neurology (Mar. 1994), vol. 53, No. 2, pp. 158-164.
[cited by applicant]
Bondareff et al., Immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease. J Neuropathol Exp Neurol. Mar. 1994;53(2):158-64. doi:10.1097/00005072-199403000-00007.
[cited by applicant]
Braak et al., “Alzheimer's Disease: Transiently Developing Dendritic Changes in Pyramidal Cells of Sector CA1 of the Ammon's Horn,” Acta Neuropathol., 1997, pp. 323-325, vol. 93.
[cited by applicant]
Brandt, “Cytoskeletal Mechanisms of Axon Outgrowth and Pathfinding,” Cell Tissue Res., 1998, pp. 181-189, vol. 292.
[cited by applicant]
Brion et al., “Characterization of a Partial cDNA Specific for the High Molecular Weight Microtubule-Associated Protein MAP2 That Encodes Epitopes Shared with Paired Helical Filaments of Alzheimer's Disease,” Dementia, …
[cited by applicant]
Butterfield et al., Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev. Jul. 15, 2001;122(9):945-62. doi:10.1016/s0047-6374(01)00249-4.
[cited by applicant]
Byrne et al., “Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis”, J Neurol Neurosurg Psychiatry, doi:10.1136/jnnp.2010.224501, Nov. 3, 2010, pp. 1-5.
[cited by applicant]
Callaway et al., “Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats”. Neuroscience Letters. 2002. vol. 332, pp. 83-86.
[cited by applicant]
Caputo et al., “Amyloid-like properties of a synthetic peptide corresponding to the carboxy terminus of β-amyloid protein precursor,” Archives of Biochemistry and Biophysics, 1992, vol. 292, No. 1, pp. 199-205.
[cited by applicant]
Caputo et al., “The amyloid proteins of Alzheimer's disease as potential targets for drug therapy,” Neurobiology of Aging, Feb. 21, 1989, vol. 10, pp. 451-461.
[cited by applicant]
Cavaliere et al., “Binding of methylene blue to a surface cleft inhibits the oligomerization and brillization of prion protein”, Biochimica Biophysica Acta, vol. 1832, pp. 20-28 (2013).
[cited by applicant]
Chemical Abstracts Service, XP002661598. Database Accession No. 1236208-20-0, 1 page (2010).
[cited by applicant]
Chen-Plotkin et al., “TAR DNA-binding protein 4'3 in neurodegenerative disease”, Nature Reviews Neurology, Apr. 2010, vol. 6, pp. 211-220.
[cited by applicant]
Claims examined in Notification of Reexamination for CN Application No. 201510002365.2, mailed Dec. 19, 2019.
[cited by applicant]
Condamines et al., “New immunoassay for the mapping of neurofibrillary degeneration in Alzheimer's disease using two monoclonal antibodies against human paired helical filament tau proteins,” Neuroscience Letters, Jun. …
[cited by applicant]
Contineanu et al., Radiolysis of Methylene Blue Studied by ESR. Radiochem. Radioanal. Letters. 1983; 57(1): 9-22.
[cited by applicant]
Cox et al., “Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS)”, PLoS ONE, Mar. 2010, vol. 5, No. 3, e9872, pp. 1-16.
[cited by applicant]
Cudd et al., “Pharmacokinetics and toxicity of tolonium chloride in sheep”, Vet Human Toxicol, vol. 38, No. 5, Oct. 1996, pp. 329-334.
[cited by applicant]
Day, “How to Write and Publish a Scientific Paper,” 1983, pp. 124-127, ISI Press, Philadelphia, PA.
[cited by applicant]
De Ancos et al., “Differences in Microtubule Binding and Self-association Abilities of Bovine Brain Tau Isoforms”, Journal of Biological Chemistry, 1993, pp. 7976-7982, vol. 268(11).
[cited by applicant]
Declaration Under 37 C. F. R. § 1.132 by Professor Claude Wischik, filed on Feb. 9, 2018.
[cited by applicant]
Declaration Under 37 C. F. R. § 1.132 by Professor John Storey, filed on Feb. 9, 2018.
[cited by applicant]
Declaration Under 37 C.F.R. § 1.132 by Dr. Stephen Hilton, filed on Jul. 14, 2020.
[cited by applicant]
Deture et al., “In vitro assembly of Alzheimer-like filaments. How a small cluster of charged residues in tau and MAP2 controls filament morphology,” Journal of Biological Chemistry, 2002, vol. 277, pp. 34755-34759.
[cited by applicant]
Drew et al., Derivatives of Methylene-blue. Journal of the Chemical Society. 1933:248-253.
[cited by applicant]
Elden et al., “Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS”, Nature, doi:10.1038/nature09320, Aug. 26, 2010, vol. 466, pp. 1069-1075.
[cited by applicant]
Epstein et al., “The utility of toluidine blue application as a diagnostic aid in patients previously treated for upper oropharyngeal carcinoma”, Oral medicine, (1997), pp. 537-547, vol. 83, No. 5.
[cited by applicant]
Fasulo et al., “Overexpression of Alzheimer's PHF core tau fragments: implications for the tau truncation hypothesis,” Rapid Science Publishers, Alzheimer's Research, vol. 2, No. 5, pp. 195-200, Oct. 1996.
[cited by applicant]
Finsterer, “Mitochondrial disorders, cognitive impairment and dementia”, Journal of the Neurological Sciences, 2009, vol. 283, pp. 143-148, doi:10.1016/j.jns.2009.02.347.
[cited by applicant]
Friedhoff et al., “A nucleated assembly mechanism of Alzheimer paired helical filaments”, PNAS, 1998, pp. 15712-15717, vol. 95.
[cited by applicant]
Friedhoff et al., “Rapid Assembly of Alzheimer-like Paired Helical Filaments from Microtubule-Associated Protein Tau Monitored by Fluorescence in Solution”, Biochemistry, 1998, pp. 10223-10230, vol. 37.
[cited by applicant]
Garcini et al., “In Vitro Conditions for the Self-Polymerization of the Microtubule-Associated Protein, Tau Factor,” J. Biochem., 1987, pp. 1415-1421, vol. 102, No. 6.
[cited by applicant]
Garcini et al., Self Assembly of Microtubule Associated Protein TAU into Filaments Resembling those found in Alzheimer Disease, Biochemical and Biophysical Research Communications, 1988, pp. 790-797.
[cited by applicant]
Garcini et al., FEBS Letters, “Tau Factor Polymers are Similar to Paired Helical Filaments of Alzheimer's Disease,” 1988, vol. 236, No. 1, pp. 150-154, Elsevier Science Publishers B.V.
[cited by applicant]
Gaudette et al., Determination of methylene blue and leucomethylene blue in male and female Fischer 344 rat urine and B6C3F1 mouse urine. J Anal Toxicol. Jan.-Feb. 2005;29(1):28-33. doi: 10.1093/jat/29.1.28.
[cited by applicant]
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
[cited by applicant]
Gendron et al., Review: Transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration, Neuropathology and Applied Neurobiology, 2010, vol. 36, pp. 97-112, doi:10.1111/j.1365-2990.2009.01060.x.
[cited by applicant]
Gertz et al., “Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease”, Aeta Neuropathol (1998), vol. 95, pp. 154-158.
[cited by applicant]
Gertz et al., “The relationship between clinical dementia and neuropathological staging (Braak) in a very elderly community sample”, Eur Arch Psychiatry Clin Neurosci (1996) vol. 246, pp. 132-136.
[cited by applicant]
Geser et al., “Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: A spectrum of TDP-43 proteinopathies”, Neuropathology, 2010, vol. 30, 103-112.
[cited by applicant]
Giannetti et al., “Fibers of tau fragments, but not full length tau, exhibit a cross (β-structure: implications for the formation of paired helical filaments,” Protain Science, 2000, vol. 9, pp. 2427-2435.
[cited by applicant]
Giorgini et al., Connecting the dots in Huntington's disease with protein interaction networks. Genome Biol. 2005;6(3):210. doi: 10.1186/GB-2005-6-3-210. Epub Feb. 28, 2005.
[cited by applicant]
Gitcho et al., “TDP-43 A315T Mutation in Familial Motor Neuron Disease”, Ann Neurol, 2008, vol. 63, pp. 535-538.
[cited by applicant]
Goedert et al., “Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau,” Proc. Natl. Acad. Sci. USA, Jun…
[cited by applicant]
Goedert et al., “Tau Proteins of Alzheimer Paired Helical Filaments: Abnormal Phosphorylation of All Six Brain Isoforms,” Neuron, Jan. 1992, pp. 159-168, vol. 8.
[cited by applicant]
Goedert et al., Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. Jun. 19…
[cited by applicant]
Götz et al., “Tau filaments formation in transgenic mice expressing P301L tau,” J. Biol. Chem., Jan. 5, 2001, vol. 276(1), pp. 529-534.
[cited by applicant]
Grover et al., “5′ Splice Site Mutations in Tau Associated with the Inherited Dementia FTDP-17 Affect a Stem-Loop Structure That Regulates Alternative Splicing of Exon 10*,” The Journal of Biological Chemistry, May 21, …
[cited by applicant]
Grundke-Iqbal et al., “Abnormal phosphorylation of microtubule-associated protein T (tau) in Alzheimer cytoskeletal pathology,” Proc. Natl. Acad. Sci. USA 83(13): 4913-4917 (1986).
[cited by applicant]
Hagestedt et al., “Tau protein becomes long and stiff upon phosphorylation: correlation between paracrystalline structure and degree of phosphorylation,” The Journal of cell biology, 1989, vol. 109, pp. 1643-1651.
[cited by applicant]
Han et al., Medicament Manufacture Technology. Mar. 2000. First Edition. Chapter 1. Science and Technology Literature Press, Eds. pp. 215-216.
[cited by applicant]
Harada et al., “Altered Microtubule Organization In Small-Calibre Axons of Mice Lacking Tau Protein,” Letters to Nature, Jun. 9, 1994, vol. 369, pp. 488-489.
[cited by applicant]
Harrington et al., “Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease”, The Journal of Biological Chemistry, vol. 290, N…
[cited by applicant]
Harrington et al., “Competitive ELISA for the Measurement of Tau Protein in Alzheimer's Disease,” Journal of Immunological Methods, 1990, pp. 261-271, vol. 134.
[cited by applicant]
Harrington et al., “Measurement of Distinct Immunochemical Presentations of Tau Protein in Alzheimer Disease,” Proc. Natl. Acad. Sci., Jul. 1991, pp. 5842-5846, vol. 88.
[cited by applicant]
Higashi et al., “TDP-43 physically interacts with amyotrophic lateral sclerosis-linked mutant CuZn superoxide dismutase”, Neurochemistry International, 2010, vol. 57, pp. 906-913.
[cited by applicant]
Higson et al., Iron enhancement of ascorbate toxicity. Free Radic Res Commun. 1988;5(2):107-15. doi: 10.3109/10715768809066918.
[cited by applicant]
Hochgräfe et al., “Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau”, Acta Neuropathologica Communications, 3:25 (2015).
[cited by applicant]
Holoubek et al., “Toluidine blue in bleeding associated with thrombopenia”, J.A.M.A., Jan. 22, 1949, vol. 139, No. 4, pp. 214-216.
[cited by applicant]
Hosokawa, “Methylene Blue Reduced Abnormal Tau Accumulation in P3011 Tau Transgenic Mice”, PLoS ONE, vol. 7, No. 12, e52389 (2012).
[cited by applicant]
Hutton et al., “Association of Missense and 5′-splice-site Mutations in Tau With the Inherited Dementia FTDP-17,” Nature, Jun. 18, 1998, pp. 702-705, vol. 393.
[cited by applicant]
Igaz et al., “Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies”, The Journal of Biological Chemistry, Mar. 27, 2009, vol. 284, No. 13, pp. 8516-8524.
[cited by applicant]
Ishiguro et al., “A novel tubulin-dependent protein kinase forming a paired helical filament epitope on tau,” J. Biochem, 1988, vol. 104, pp. 319-321.
[cited by applicant]
Ishiguro et al., “A serine/threonine proline kinase activity is included in the tau protein kinase fraction forming a paired helical filament epitope,” Neuroscience Letters, 1991, vol. 128, pp. 195-198.
[cited by applicant]
Ishiguro et al., “Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments,” Neuroscience Letters, 1992, vol. 148, pp. 202-206.
[cited by applicant]
Ishiguro et al., “Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments,” Journal of Biological Chemistry, 1992, vol. 267, pp. 10897-10901.
[cited by applicant]
Ishihara et al., “Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform,” Neuron, Nov. 1999, pp. 751-762, vol. 24.
[cited by applicant]
Ito. et al., “Enhancing effect of ascorbate on toluidine blue-photosensitization of yeast cells” Photochemistry and Photobiology, (1982), pp. 501-505, vol. 35.
[cited by applicant]
Jakes et al., “Identification of 3-and 4-repeat Tau Isoforms within the PHF in Alzheimer's Disease,” The EMBO Journal, 1991, pp. 2725-2729, vol. 10, No. 10.
[cited by applicant]
Janciauskiene et al., “In vitro amyloid fibril formulation from (α1-antitrypsin,” Bio Chem, 1995, vol. 375, pp. 103-109.
[cited by applicant]
Jellinger, Interaction between α-synuclein and other proteins in neurodegenerative disorders. Scientific WorldJournal. 2011;11:1893-907. doi: 10.1100/2011/371893. Epub Oct. 24, 2011.
[cited by applicant]
Jinwal et al., “Chemical Manipulation of Hsp70 ATPase Activity Regulates Tau Stability”, J. Neurosci., Sep. 30, 2009, vol. 29, No. 39, pp. 12079-12088.
[cited by applicant]
Johnson et al., “A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity”, PNAS, Apr. 29, 2008, vol. 105, No. 17, pp. 6439-6444.
[cited by applicant]
Johnson et al., “Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS”, Neuron, Dec. 9, 2010, vol. 68, pp. 857-864.
[cited by applicant]
Johnson et al., “TDP-43 is Intrinsically Aggregation-prone, and Amyotrophic Lateral Sclerosis-linked Mutations Accelerate Aggregation and Increase Toxicity”, The Journal of Biological Chemistry, Jul. 24, 2009, vol. 284,…
[cited by applicant]
Kabashi et al., “Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo”, Human Molecular Genetics, 2010, vol. 19, No. 4, pp. 671-683, doi:10.1093/hmg/ddp534.
[cited by applicant]
Kabashi et al., “TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis”, Nature Genetics, May 2008, vol. 40, No. 5, pp. 572-574.
[cited by applicant]
Kaech et al., “Cytoskeletal Plasticity in Cells Expressing Neuronal Microtubule-Associated Proteins,” Neuron, Dec. 1996, pp. 1189-1199, vol. 17.
[cited by applicant]
Kiese et al., “Comparative studies on the effects of toluidine blue and methylene blue on the reduction of ferrihaemoglobin in man and dog” , Europ. J. Clin. Pharmacol., 1972, vol. 4, pp. 115-118.
[cited by applicant]
Klymkowsky, “Weaving a tangled web: the interconnected cytoskeleton”, Nature Cell Biology (1999) vol. 1, No. 5, p. E121.
[cited by applicant]
Kohler & Co., “Toluidinblau,” Drug Information, Alsbach, Germany. Jul. 1997.
[cited by applicant]
Koryta “Ions, Electrodes and Membranes”, Institute of Physiology, Second Edition, John Wiley & Sons (1991).
[cited by applicant]
Ksiezak-Reding et al., Assembled tau filaments differ from native paired helical filaments as determined by scanning transmission electron microscopy (STEM), Brain Research (1998), vol. 814, pp. 86-98.
[cited by applicant]
Ksiezak-Reding et al., “Mass and Physical Dimensions of Two Distinct Populations of Paired Helical Filaments,” Neurobiology of Aging, 1993, pp. 11-18, vol. 15, No. 1.
[cited by applicant]
Ksiezak-Reding et al., “Structural Stability of Paired Helical Filaments Requires Microtubule-Binding Domains of Tau: A Model for Self-Association,” Neuron, 1991, pp. 717-728, vol. 6.
[cited by applicant]
Lai et al., “Examination of Phosphorylated Tau Protein as a PHF-Precursor at Early State Alzheimer's Disease,” Neurobiology of Aging, May-Jun. 1995, pp. 433-445, vol. 16, No. 3.
[cited by applicant]
Lai R., “The Role of Abnormal Phosphorylation of Tau Protein in the Development of Neurofibrillary Pathology in Alzheimer's Disease”—Submitted for the Degree of Doctor of Philosophy at the University of Cambridge, Chris…
[cited by applicant]
Ledesma et al., “Implication of brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in Alzheimer's disease,” FEBS, 1992, vol. 308, No. 2, pp. 218-224.
[cited by applicant]
Lee et al., “A68: A Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau,” Science, 1991, pp. 675-678, vol. 251.
[cited by applicant]
Lee et al., “Tau Proteins and their significance in the Pathobiology of Alzheimer's Disease,” Pathobiology of Alzheimer's Disease, 1995, ISBN 0-12-286965-5, pp. 41-58.
[cited by applicant]
Lee et al., untitled, Science, 1992., vol. 251.
[cited by applicant]
Lewis et al., “Microtubule-Associated Protein MAP2 Shares a Microtubule Binding Motif with Tau Protein”, Science(Nov. 11, 1988) vol. 242, pp. 936-939.
[cited by applicant]
Lichtenberg-Kraag et al., “Alzheimer-Type Phosphorylation of Microtubule-Associated Protein Tau In Vitro”, 1991/92.
[cited by applicant]
Lichtenberg-Kraag et al., “Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau”, Proc. Natl. Acad. Sci (Jun. 1992) vol. 89, pp. 5384-5388.
[cited by applicant]
Ling et al., “ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS”, PNAS, Jul. 27, 2010, vol. 107, No. 30, pp. 13318-13323.
[cited by applicant]
Link, “Targeting Melanoma with 211 At/131I-Methylene Blue: Preclinical and Clinical Experience”, Hybridoma (Nov. 1, 1999), vol. 18, No. 1, pp. 77-82.
[cited by applicant]
Lomas et al., “The mechanism of Z alpha1-antitrypsin accumulation in the liver”, Letters of Nature (Jun. 18, 1992), vol. 357, pp. 605-607.
[cited by applicant]
Love et al., “Neurofibrillary tangles in Niemann-Pick disease type C”, Brain, 1995, vol. 118, pp. 119-129.
[cited by applicant]
Mackenzie et al., “TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia”, Lancet Neurol, Oct. 2010, vol. 9, pp. 995-1007.
[cited by applicant]
Mackenzie I.R.A et al., “Pathological TDP-43 Distinguishes Sporadic Amyotrophic Lateral Sclerosis from Amyotrophic Lateral Sclerosis with SOD1 Mutations”, Ann Neurol, 2007, vol. 61, pp. 427-434.
[cited by applicant]
Makaetova-Ladinska et al., “Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease”, American Journal of Pathology (Aug. …
[cited by applicant]
Martinez et al., “Methylene blue alters retention of inhibitory avoidance responses”, Physiol. Psychol., 1978, vol. 6, No. 3, pp. 387-390.
[cited by applicant]
Mashberg A., “Tolonium (Toluidine blue) rinse—a screening method for recognition of squanous carcinoma—continuing study of oral-cancer 4,” Jama-Journal of the American Medical Association, Jun. 19, 1981, vol. 245 No. 23…
[cited by applicant]
Masuda et al., Small molecule inhibitors of (a-synuclein filament assembly. Biochemistry, (2006), pp. 6085-6094, 45.
[cited by applicant]
May et al., “Reduction and uptake of methylene blue by human erythrocytes”, Am J Physiol Cell Physiol , 286, 2004, pp. C1390-C1398.
[cited by applicant]
Mayo Clinic staff, Alzheimer's prevention: Does it exist? Aug. 31, 2010. Retrieved from http://www.mayoclinic.com/health/alzheimersprevention/AN02099/METHOD=print on Sep. 25, 2012.
[cited by applicant]
Melis et al., “Effects of oxidised and reduced forms of Methylthioninium in two transgenic mouse tauopathy models”, Behavioural Pharmacology, vol. 26, No. 4, pp. 353-368 (2015).
[cited by applicant]
Mena et al., “A Progressive Deposition of Paired Helical Filaments (PHF) in the Brain Characterizes the Evolution of Dementia in Alzheimer's Disease,” Journal of Neuropathology and Experimental Neurology, 1991, pp. 474-…
[cited by applicant]
Mena et al., “Monitoring Pathological Assembly of tau and (β-Amyloid Proteins in Alzheimer's Disease,” Acta Neuropathol., 1994, pp. 50-56.
[cited by applicant]
Mena et al., “Staging the Pathological Assembly of Truncated tau Protein into Paired Helical Filaments in Alzheimer's Disease,” Acta Neuropathol, 1996, pp. 633-641.
[cited by applicant]
Mohideen et al., “Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies”, Scientific Reports, 5:10821 | DOi:10.1038/srep10821, pp. 1-14 (2015).
[cited by applicant]
Mukaetova-Ladinska et al., “Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease”, American Journal of Pathology (Aug. …
[cited by applicant]
Müller T., “Light-microscopic demonstration of methylene blue accumulation sites in mouse brain after supravital staining”, Acta Anat., 1992, vol. 144, pp. 39-44.
[cited by applicant]
Murthy et al., Cyclic-voltametric studies of some phenothiazine dyes. J. Chem. Soc., Faraday Transactions 1. 1984;80:2745-2750.
[cited by applicant]
Neary et al., “Frontotemporal lobar degeneration—A consensus on clinical diagnostic criteria”, Neurology, 1998, vol. 51, pp. 1546-1554.
[cited by applicant]
Neumann et al., “Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis”, Science, Oct. 6, 2006, vol. 314, pp. 130-133.
[cited by applicant]
Neumann, “Molecular Neuropathology of TDP-43 Proteinopathies”, Int. J. Mol. Sci., 2009, vol. 10, pp. 232-246, doi:10.3390/ijms10010232.
[cited by applicant]
Nonaka et al., “Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43”, Human Molecular Genetics, 2009, vol. 18, No. 18, pp. 3353-3364, doi:10.1093/hmg/ddp275.
[cited by applicant]
Novak et al., “Molecular Characterization of the Minimal Protease Resistant Tau Unit of the Alzheimer's Disease Paired Helical Filament,” The EMBO Journal, 1993, pp. 365-370, vol. 12, No. 1.
[cited by applicant]
Ohmi et al., “Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy”, PNAS, May 19, 2009, vol. 106, No. 20, 8332-8337.
[cited by applicant]
Orr et al., “Trinucleotide Repeat Disorders”, Annu. Rev. Neurosci., vol. 30, pp. 575-621 (2007).
[cited by applicant]
Pedrotti et al., “Interactions of Microtubule-Associated Protein MAP2 with Unpolymerized and Polymerized Tubulin and Actin Using a 96-Well Microtiter Plate Solid-Phase Immunoassay”; Biochemistry 1994 33:8798-8806.
[cited by applicant]
Perez et al., “In vitro assembly of tau protein: Mapping the regions involved in filament formation,” Biochemistry, 2001, vol. 40, 5983-5991.
[cited by applicant]
Perez-Tur et al., “Neurodegenerative disease of Guam: Analysis of TAU,” American Academy of Neurology, 1999, vol. 53, pp. 411-412.
[cited by applicant]
Pickhardt et al., “Anthraquinones inhibit tau aggregation and dissolve Alzheimer paired helical filaments in vitro and in cells,” Journal of Biological Chemistry, 2005, vol. 280, pp. 3628-3635.
[cited by applicant]
Poulter et al., “Locations and immunoreactivities of phosphorylation sites on bovine and porcine tau proteins and a PHF-tau fragment,” The Journal of Biological Chemistry, 1993, vol. 268, No. 13, pp. 9636-9644.
[cited by applicant]
Raust et al., Stability studies of ionised and non-ionised 3,4-diaminopyridine: Hypothesis of degradation pathways and chemical structure of degradation products. Journal of Pharmaceutical and Biomedical Analysis. 2007;…
[cited by applicant]
Ross et al., Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol. Nov. 2005;6(11):891-8. doi: 10.1038/nrm1742.
[cited by applicant]
Rumbolz et al., “Use of protamine sulfate and toluidine blue for abnormal uterine bleeding,” Am. J. Obst. & Gynec., May 1952, vol. 63, No. 5, pp. 1029-1037.
[cited by applicant]
Sato-Harada et al., “Microtubule-associated Proteins Regulate Microtubule Function as the Track for Intracellular Membrane Organelle Transports,” Cell Structure and Function, 1996, pp. 283-295, vol. 21.
[cited by applicant]
Schneider et al., “Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments,” Biochemistry, 1999, vol. 38, pp. 3549-3558.
[cited by applicant]
Schwab et al., A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy. Frontiers in Molecular Neuroscience. Ja…
[cited by applicant]
Seetharaman et al., “Immature Copper-Zinc Superoxide Dismutase and Familial Amyotrophic Lateral Sclerosis”, Exp Biol Med (Maywood), Oct. 2009, vol. 234, No. 10, pp. 1140-1154, doi:10.3181/0903-MR-104.
[cited by applicant]
Seilhean et al., “Accumulation of TDP-43 and α-actin in an amyotrophic lateral sclerosis patient with the K17I ANG mutation”, Acta Neuropathol, 2009, vol. 118, pp. 561-573, doi:10.1007/s00401-009-0545-9.
[cited by applicant]
Shiyu, Synthetic drugs and intermediates Manual. 2003. Chapter 4. Beijing Chemical Industry Press, Eds. p. 285.
[cited by applicant]
Shojania, et al., “The effect of toluidine blue and methylene blue in immunochemical reactions in vitro”, Clinical Immunology and Immunopathology, (1987), pp. 223-228, 43.
[cited by applicant]
Shumin, Medicinal Chemistry. 2014. Shandong People's Publishing House, Eds. pp. 113- 116.
[cited by applicant]
Sigfridsson et al., A case study where pharmaceutical salts were used to address the issue of low in vivo exposure. Drug Development and Industrial Pharmacy. 2019;45(2):202-211. DOI 10.1080/03639045.2018.1529184.
[cited by applicant]
Sigma Biosciences, “In vitro toxicology assay kit lactate dehydrogenase based,” Cell Viability (2009).
[cited by applicant]
Smith et al., “The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process?,” Neuropathology and Applied Neurobiology, 1994, pp. 322 338, vol. 20, XP002002176.
[cited by applicant]
Solomons, Organic Chemistry. 1984. 3rd Edition. John Wiley & Sons Inc., Eds. pp. 62 and 850.
[cited by applicant]
Sontag et al., “Methylene Blue Modulates Huntingtin Aggregation Intermediates and Is Protective in Huntington's Disease Models”, The Journal of Neuroscience, vol. 32, No. 32, pp. 11109-11119 (2012).
[cited by applicant]
Sreedharan et al., “TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis”, Science, Mar. 21, 2008, vol. 319, pp. 1668-1672, doi:10.1126/science.1154584.
[cited by applicant]
Swarbrick, Encyclopedia of Pharmaceutical Technology. Third Edition. vol. 1. 2007. Informa Healthcare USA, Inc., eds. pp. 3003 and 3178.
[cited by applicant]
Taniguchi et al., “Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.” JBC Papers in Press, 2004, Manuscript M408714200.
[cited by applicant]
Tint et al., “Acute Inactivation of Tau Has No Effect on Dynamics of Microtubules in Growing Axons of Cultured Sympathetic Neurons,” The Journal of Neuroscience, Nov. 1, 1998, pp. 8661-8673, vol. 18, No. 21.
[cited by applicant]
Van Bebber et al., “Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish”, Neurobiology of Disease, vol. 39, pp. 265-271 (2010).
[cited by applicant]
Van Rossum et al., “Cytoskeletal Dynamics in Dendritic Spines: Direct Modulation By Glutamate Receptors?,” Trends Neurosci., 1992, pp. 290-295, vol. 22.
[cited by applicant]
Vance et al., “Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6”, Science, Feb. 27, 2009, vol. 323, pp. 1208-1211.
[cited by applicant]
Varani et al., “Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17,” Proc. Natl. Acad. Sci. USA, 1999, vol. 96, …
[cited by applicant]
Vippagunta et al., Crystalline Solids, Advance Drug Delivery Reviews (2001), 48:3-26.
[cited by applicant]
Von Bergen et al., “Assembly of tau protein into Alzheimer's paired helical filaments depends on a local sequence motif forming (306VQIVYK311) beta structure,” Proceedings of the National Academy of Sciences of USA, Nat…
[cited by applicant]
Wijesekera et al., “Amyotrophic lateral sclerosis”, Feb. 3, 2009, Orphanet Journal of Rare Diseases, 2009, vol. 4, No. 3, pp. 1-22.
[cited by applicant]
Wille et al., Alzheimer-like paired helical filaments and antiparallel dimars formed from microtubule-associated protein tau in vitro, J. Cell Biol., 1992, pp. 573-584, vol. 118.
[cited by applicant]
Wirths et al., α-Synuclein, Aβ and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. Feb. 2003;27(1):103-8. doi: 10.1016/S0278-5846(02)00339-1.
[cited by applicant]
Wischik “Cell biology of the Alzheimer tangle,” Current Opinion in Cell Biology, 1989, vol. 1, pp. 115-122.
[cited by applicant]
Wischik C., “Molecular Neuropathology of Alzheimer's Disease,” 1989, pp. 44-70.
[cited by applicant]
Wischik C., “Molecular neuropathology of Alzheimer's disease,” John Libbey & Co., 1991, pp. 239-250.
[cited by applicant]
Wischik et al., “The role of tau protein in the neurodegenerative dementias”, Dementia 2nd Edition (2000), Hodder Arnold Published, pp. 461-492.
[cited by applicant]
Wischik et al., “Author's Response to Commentaries,” Neurobiology of Aging, 1995, vol. 16, No. 3, pp. 423-431.
[cited by applicant]
Wischik et al., “Isolation of a Fragment of Tau Derived From the Core of the Paired Helical Filament of Alzheimer Disease,” Proc. Natl. Acad. Sol. USA, Jun. 1998, pp. 4506-4510, vol. 85.
[cited by applicant]
Wischik et al., “Modelling Prior-like Processing of Tau Protein in Alzheimer's disease for Pharmaceutical Development,” Harwood Acad. Publishers, 1997, pp. 185-241.
[cited by applicant]
Wischik et al., “Quantitative Analysis of Tau Protein in Paired Helical Filament Preparations: Implications for the Role of Tau Protein Phosphorylation in PHE Assembly in Alzheimer's Disease,” Neurobiology of Aging, 199…
[cited by applicant]
Wischik et al., “Structure, Biochemistry and Molecular Pathogenesis of Paired Helical Filaments in Alzheimer's Disease,” Pathobiology of Alzheimer's Disease, 1995, pp. 10-39.
[cited by applicant]
Wischik et al., “Subunit Structure of Paired Helical Filaments in Alzheimer's Disease,” The Journal of Cell Biology, 1985, vol. 100, pp. 1905-1912.
[cited by applicant]
Wischik et al., “Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease”, Journal of Alzheimer's Disease, vol. 44, pp. 705-720 (2015).
[cited by applicant]
Wischik et al., “The molecular basis of tau protein pathology in Alzheimer's disease and related neurodegenerative dementias,” In Neurobiology of Alzheimer's Disease (Eds. D. Dawbarn & S.J. Allen) Oxford University Pres…
[cited by applicant]
Wischik et al., Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S. Oct. 1, 1996;93(20):11213-8. doi:10.1073/pnas.93.20.11213.
[cited by applicant]
Wischik et al., Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. Jul. 1988;85(13):4884-8.
[cited by applicant]
Wischik, Dissertation by Claude Wischik. May 19, 1989. pp 182, 189, 233 and 234.
[cited by applicant]
Wischik, The Structure and Biochemistry of Paired Helical Filaments in Alzheimer's Disease, Part I and II. Thesis for Cambridge University. May 1989. pp. 1-455.
[cited by applicant]
Wischik, Thesis, “The Structure and Biochemisty of Paired Helical Filaments in Alzheimer's Disease”, Part I and II, Cambridge University, May 19, 1989, pp. 182, 189, 232-234.
[cited by applicant]
Wood et al., Protein aggregation in motor neurone disorders. Neuropathology and Applied Neurobiology. 2003;29:529-545.
[cited by applicant]
Yale et al., 4-{3-[10-(2-Trifluoromethyl)-phenothiazinyl]-propyl}-1-piperazine-ethanol1 and Related Compounds. Squibb Institute for Medical Research. Apr. 20, 1960;82: 2039-2042.
[cited by applicant]
Yamashita et al., “Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models”, FEBS Letters, 2009, vol. 583, pp. 2419-2424.
[cited by applicant]
Yen, et al., “Alzheimer's Neurofibrillary Tangles Contain Unique Epitopes and Epitopes in Common With the Heat-Stable Microtubule Associated Proteins Tau and MAP2,” AJP, Jan. 1987, vol. 126, pp. 81-91.
[cited by applicant]
Zhang, et al., “Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity”, PNAS, May 5, 2009, vol. 106, No. 18, pp. 7607-7612.
[cited by applicant]
Zhang, et al., “Methylene Blue Prevents Neurodegeneration Caused by Rotenone in the Retina”, Neurotoxicity Research, vol. 9, No. 1, 2006, pp. 47-57.
[cited by applicant]
U.S. Appl. No. 18/760,513, filed Jul. 1, 2024, Marshall et al.
[cited by applicant]
U.S. Appl. No. 18/725,043, filed Jun. 27, 2024, Agarwal et al.
[cited by applicant]
U.S. Appl. No. 18/849,744, filed Sep. 23, 2024, Harrington et al.
[cited by applicant]
U.S. Appl. No. 18/869,709, filed Nov. 26, 2024, Wischik et al.
[cited by applicant]
Guttmann et al., Uber die wirkung des methylenblau bei malaria. 1st Edition. Berl Klin Woschenr. 1891; 28: 953-956. https://doi.org/10.1016/B978-0-08-009056-6.50006-3.
[cited by applicant]
Rengelshausen et al., Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol. Dec. 2004;60(10):709-15. doi:10.1007/s00228-004-0818-0. Epub Oct. 13, 2004.
[cited by applicant]
Schirmer et al., Methylene blue as an antimalarial agent. Redox Rep. 2003;8(5):272-5. doi:10.1179/135100003225002899.
[cited by applicant]